Seven HKTDC Lifestyle Fairs Power Sourcing and Showcase Hong Kong’s Creative Industries
17.4.2026 14:19:00 CEST | Business Wire | Press Release
The Hong Kong Trade Development Council (HKTDC) is hosting seven mega events, including Hong Kong Gifts & Premium Fair, Home InStyle and Fashion InStyle (27-30 April at the Hong Kong Convention and Exhibition Centre, HKCEC); the Hong Kong International Printing & Packaging Fair and DeLuxe PrintPack Hong Kong (held concurrently at AsiaWorld-Expo); and the Hong Kong International Licensing Show and Asian Licensing Conference (27-29 April at the HKCEC). These events bridge Hong Kong's creative industries with Chinese Mainland and global markets, reinforcing the city’s role as a regional creative hub.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260415398629/en/
Seven HKTDC Lifestyle Fairs
Trendsetting Gifts Ignite Sourcing
The Gifts & Premium Fair will feature the acclaimed Hall of Fine Designs, a key showcase for leading design brands from around the world. This edition will welcome the debut of Shanxi Pavilion, alongside an expanded Zhejiang Pavilion, led for the first time by the Department of Commerce of Zhejiang Province. In addition, Smart Design Global will present its shortlisted entries, leveraging the fair as a platform to promote original Hong Kong designs to international markets.
Leading Houseware Trends
Home InStyle continues to showcase innovative materials in houseware. Building on last year’s success with novel home solutions for the silver market, the fair brings these elements together in the Gerontech and Innovative Material Pavilion, funded by the HKSAR Government's Innovation and Technology Commission.
Redefining the Material Frontier at Fashion InStyle
Fashion InStyle marks the return of NEXT@Fashion InStyle, a premier HKTDC spotlight zone sponsored by the Cultural and Creative Industries Development Agency (CCIDA) of the HKSAR Government. Featuring the Philippines as this year’s Featured Partner, the zone unites around 60 global exhibitors showcasing how next-gen materials drive industry transformation. Guided by Project Consultant Han Chong (Self-Portrait founder), it presents five cross-disciplinary projects by six emerging Hong Kong designers.
Two PrintPack Fairs: Smart + Sustainable
The Printing & Packaging Fair will feature smart packaging & new materials alongside its green offerings, meeting rising demand for innovation and sustainability. DeLuxe PrintPack Hong Kong will focus on premium printing and packaging solutions for luxury items, with dedicated themes for industries.
The events will feature a wide range of thematic seminars, buyer forums, product promotion and launch events and fashion parades, covering market analysis, cultural creative design, smart industry, the silver economy, and sustainability.
Register Now: https://tinyurl.com/5denzja3
View source version on businesswire.com: https://www.businesswire.com/news/home/20260415398629/en/
Contacts
Media Enquiries
HKTDC's Exhibitions Department:
Pak Wong
(852) 2240 4062
pakwong@hktdc.org
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Qualcomm Announces Quarterly Cash Dividend17.4.2026 15:00:00 CEST | Press Release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.92 per common share, payable on June 25, 2026, to stockholders of record at the close of business on June 4, 2026. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing business
Qualcomm Announces Quarterly Cash Dividend17.4.2026 15:00:00 CEST | Press Release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.92 per common share, payable on June 25, 2026, to stockholders of record at the close of business on June 4, 2026. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing business
Byondis to Present Data from its Novel ADC Technology Platforms at the American Society for Cancer Research Meeting 202617.4.2026 13:00:00 CEST | Press Release
Byondis B.V., an independent biopharmaceutical company creating innovative targeted medicines for patients with cancer, will profile the Company’s first-in-class antifolate and phosphonate antibody-drug conjugate (ADC) technology platforms in poster sessions at the American Society for Cancer Research (AACR) Annual Meeting 2026 in San Diego, CA, from today through to 22 April. Wim Dokter, PhD, Chief Scientific Officer at Byondis, said: “The research we are presenting at AACR highlights the potential of two of our state-of-the-art ADC technology platforms to address significant limitations with current therapeutic approaches in cancer treatment. Our first-in-class antifolate linker-drug platform features an orthogonal mechanism of action based on clinically validated biology. This approach is engineered to address acquired resistance that can develop with current ADC treatments, positioning it for use across treatment lines. Our phosphonate linker-drug platform offers a complementary me
Byondis to Present Data from its Novel ADC Technology Platforms at the American Society for Cancer Research Meeting 202617.4.2026 13:00:00 CEST | Press Release
Byondis B.V., an independent biopharmaceutical company creating innovative targeted medicines for patients with cancer, will profile the Company’s first-in-class antifolate and phosphonate antibody-drug conjugate (ADC) technology platforms in poster sessions at the American Society for Cancer Research (AACR) Annual Meeting 2026 in San Diego, CA, from today through to 22 April. Wim Dokter, PhD, Chief Scientific Officer at Byondis, said: “The research we are presenting at AACR highlights the potential of two of our state-of-the-art ADC technology platforms to address significant limitations with current therapeutic approaches in cancer treatment. Our first-in-class antifolate linker-drug platform features an orthogonal mechanism of action based on clinically validated biology. This approach is engineered to address acquired resistance that can develop with current ADC treatments, positioning it for use across treatment lines. Our phosphonate linker-drug platform offers a complementary me
Orthogon Therapeutics Raises an Additional $11M Financing for Its BK Virus Antiviral Drug Program17.4.2026 09:34:00 CEST | Press Release
Orthogon Therapeutics today announced the closing of a follow-on $11 million financing, bringing its total capital raised to $36 million. This financing supports the continued advancement of its first-in-class drug against BK polyomavirus. BK virus infections are a major cause of complications in transplant patients, with no approved treatments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260417911548/en/ Electron microscope image of BK virus, showing the VP1 capsid protein that creates an icosahedral shell around the viral genome. The company is pioneering an oral therapy that addresses the full spectrum of BK infection, from early reactivation through systemic spread and onset of severe disease. By targeting viral proteins previously considered inaccessible to small molecule drugs, Orthogon is advancing a solution where other therapeutic modalities have fallen short. Orthogon’s lead asset uniquely targets the viral caps
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom